The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study
Open accessAbstract
Background: Evidence is conflicting about how human immunodeficiency virus (HIV) modulates coronavirus disease 2019 (COVID-19). We compared the presentation characteristics and outcomes of adults with and without HIV who were hospitalized with COVID-19 at 207 centers across the United Kingdom and whose data were prospectively captured by the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) World Health Organization (WHO) Clinical Characterization Protocol (CCP) study. Methods: We used Kaplan-Meier methods and Cox regression to describe the association between HIV status and day-28 mortality, after separate adjustment for sex, ethnicity, age, hospital acquisition of COVID-19 (definite hospital acquisition excluded), presentation date, 10 individual comorbidities, and disease severity at presentation (as defined by hypoxia or oxygen therapy). Results: Among 47 592 patients, 122 (0.26%) had confirmed HIV infection, and 112/122 (91.8%) had a record of antiretroviral therapy. At presentation, HIV-positive people were younger (median 56 vs 74 years; P < .001) and had fewer comorbidities, more systemic symptoms and higher lymphocyte counts and C-reactive protein levels. The cumulative day-28 mortality was similar in the HIV-positive versus HIV-negative groups (26.7% vs. 32.1%; P = .16), but in those under 60 years of age HIV-positive status was associated with increased mortality (21.3% vs. 9.6%; P < .001 [log-rank test]). Mortality was higher among people with HIV after adjusting for age (adjusted hazard ratio [aHR] 1.47, 95% confidence interval [CI] 1.01–2.14; P = .05), and the association persisted after adjusting for the other variables (aHR 1.69; 95% CI 1.15–2.48; P = .008) and when restricting the analysis to people aged <60 years (aHR 2.87; 95% CI 1.70–4.84; P < .001). Conclusions: HIV-positive status was associated with an increased risk of day-28 mortality among patients hospitalized for COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254 · cited 1×
“increase the severity of COVID-19 [1-5].”
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481 · cited 4×
“It is also noteworthy that mortality in the overall ISARIC CCP-UK population was higher than that reported in the New York study [21] and other countries [1].”
InfluentialSelf-citationInitiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
The INSIGHT START Study Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506816 · Cited by 2,798
COVID-19 and its implications for thrombosis and anticoagulation
Connors, J. M., & Levy, J. H. (2020) · Blood · doi:10.1182/blood.2020006000 · Cited by 2,369
May, M. T., Gompels, M., Delpech, V., Porter, K., Orkin, C., Kegg, S., Hay, P., Johnson, M., Palfreeman, A., Gilson, R., et al. (2014) · AIDS · doi:10.1097/qad.0000000000000243 · Cited by 593
Self-citationCOVID-19 in patients with HIV: clinical case series
Blanco, J. L., Ambrosioni, J., Garcia, F., Martínez, E., Soriano, A., Mallolas, J., & Miro, J. M. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30111-9 · Cited by 414
COVID-19 pandemic—a focused review for clinicians
Cevik, M., Bamford, C. G. G., & Ho, A. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.04.023 · Cited by 392
Self-citationDescription of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort
Vizcarra, P., Pérez-Elías, M. J., Quereda, C., Moreno, A., Vivancos, M. J., Dronda, F., Casado, J. L., Moreno, S., Pérez-Elías, M. J., Fortún, J., et al. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30164-8 · Cited by 373
Residual Immune Dysregulation Syndrome in Treated HIV infection
Lederman, M. M., Funderburg, N. T., Sekaly, R. P., Klatt, N. R., & Hunt, P. W. (2013) · Advances in Immunology · doi:10.1016/b978-0-12-407707-2.00002-3 · Cited by 348
del Amo, J., Polo, R., Moreno, S., Díaz, A., Martínez, E., Arribas, J. R., Jarrín, I., & Hernán, M. A. (2020) · Annals of Internal Medicine · doi:10.7326/m20-3689 · Cited by 324
COVID-19 Among People Living with HIV: A Systematic Review
Mirzaei, H., McFarland, W., Karamouzian, M., & Sharifi, H. (2021) · AIDS and Behavior · doi:10.1007/s10461-020-02983-2 · Cited by 260
COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients
Härter, G., Spinner, C. D., Roider, J., Bickel, M., Krznaric, I., Grunwald, S., Schabaz, F., Gillor, D., Postel, N., Mueller, M. C., et al. (2020) · Infection · doi:10.1007/s15010-020-01438-z · Cited by 243
Clinical Features and Outcomes of Patients With Human Immunodeficiency Virus With COVID-19
Gervasoni, C., Meraviglia, P., Riva, A., Giacomelli, A., Oreni, L., Minisci, D., Atzori, C., Ridolfo, A., & Cattaneo, D. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa579 · Cited by 236
Sigel, K., Swartz, T., Golden, E., Paranjpe, I., Somani, S., Richter, F., De Freitas, J. K., Miotto, R., Zhao, S., Polak, P., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa880 · Cited by 226
Outcomes Among HIV-Positive Patients Hospitalized With COVID-19
Karmen-Tuohy, S., Carlucci, P. M., Zervou, F. N., Zacharioudakis, I. M., Rebick, G., Klein, E., Reich, J., Jones, S., & Rahimian, J. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002423 · Cited by 220
Coronavirus disease 2019 (COVID‐19) outcomes in HIV/AIDS patients: a systematic review
Cooper, T., Woodward, B., Alom, S., & Harky, A. (2020) · HIV Medicine · doi:10.1111/hiv.12911 · Cited by 211
Davies, M.-A. (2020) · medRxiv · doi:10.1101/2020.07.02.20145185 · Cited by 192
Miller, V., Mocroft, A., Reiss, P., Katlama, C., Papadopoulos, A. I., Katzenstein, T., van Lunzen, J., Antunes, F., Phillips, A. N., Lundgren, J. D., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-7-199904060-00005 · Cited by 169
Impacts of immunosuppression and immunodeficiency on COVID-19: A systematic review and meta-analysis
Gao, Y., Chen, Y., Liu, M., Shi, S., & Tian, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.05.017 · Cited by 168
Patel, A. P., Paranjpe, M. D., Kathiresan, N., Rivas, M. A., & Khera, A. V. (2020) · International Journal for Equity in Health · doi:10.1186/s12939-020-01227-y · Cited by 142
Ho, H.-E., Peluso, M. J., Margus, C., Lopes, J. P. M., He, C., Gaisa, M. M., Osorio, G., Aberg, J. A., & Mullen, M. P. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa380 · Cited by 108
The Relationship between Age and Fever Magnitude
Roghmann, M., Mackowiak, P. A., & Warner, J. (2001) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200108000-00003 · Cited by 84
Meyerowitz, E. A., Kim, A. Y., Ard, K. L., Basgoz, N. O., Chu, J. T., Hurtado, R. M., Lee, C. K., He, W. W., Minukas, T., Nelson, S. B., et al. (2020) · AIDS · doi:10.1097/qad.0000000000002607 · Cited by 77
Harrison, E. M., Docherty, A. B., Barr, B., Buchan, I. E., Carson, G., Drake, T. M., Dunning, J. W., Fairfield, C. J., Gamble, C. L., Green, C., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3618215 · Cited by 68
Self-citationPatterns of Co-occurring Comorbidities in People Living With HIV
Francesco, D. D., Verboeket, S. O., Underwood, J., Bagkeris, E., Wit, F. W. N. M., Mallon, P. W. G., Winston, A., Reiss, P., Sabin, C. A., Babalis, D. S., et al. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy272 · Cited by 55
Self-citationCOVID‐19 research: an opinion piece
Waters, L. J., & Rockstroh, J. K. (2020) · HIV Medicine · doi:10.1111/hiv.12913 · Cited by 4
Self-citation
Cited by
Bhaskaran, K., Rentsch, C. T., MacKenna, B., Schultze, A., Mehrkar, A., Bates, C. J., Eggo, R. M., Morton, C. E., Bacon, S. C. J., Inglesby, P., et al. (2021) · The Lancet HIV · doi:10.1016/s2352-3018(20)30305-2 · Cited by 470
Comorbidities, multimorbidity and COVID-19
Russell, C. D., Lone, N. I., & Baillie, J. K. (2023) · Nature Medicine · doi:10.1038/s41591-022-02156-9 · Cited by 368
Self-citationSsentongo, P., Heilbrunn, E. S., Ssentongo, A. E., Advani, S., Chinchilli, V. M., Nunez, J. J., & Du, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-85359-3 · Cited by 325
Kent, S. J., Khoury, D. S., Reynaldi, A., Juno, J. A., Wheatley, A. K., Stadler, E., John Wherry, E., Triccas, J., Sasson, S. C., Cromer, D., et al. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00716-1 · Cited by 139
Nachega, J. B., Kapata, N., Sam-Agudu, N. A., Decloedt, E. H., Katoto, P. D. M. C., Nagu, T., Mwaba, P., Yeboah-Manu, D., Chanda-Kapata, P., Ntoumi, F., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.03.038 · Cited by 80
Metadata
- Authors
- Geretti, A. M., Stockdale, A. J., Kelly, S. H., Cevik, M., Collins, S., Waters, L., Villa, G., Docherty, A., Harrison, E. M., Turtle, L., Openshaw, P. J. M., Baillie, J. K., Sabin, C. A., & Semple, M. G.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-10-23
- Volume
- 73
- Issue
- 7
- Pages
- e2095-e2106
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W3048765898
- Cited by
- 283
- References
- 28
- FWCI
- 6.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.